About Doctor
Dr. Ahn Jin-hee is among the best oncologist in Seoul, South Korea.
- Dr. Ahn Jin-hee education
-
- Doctor of Medicine : University of Ulsan
- Master of Medicine : University of Ulsan
- Bachelor of Medicine : Hanyang University
- Dr. Ahn Jin-hee professional experiences
-
- Visiting Researcher at Danafaber Cancer institute, Harvard Medical School, USA
- Associate Professor in Oncology, UUCM AMC
- Assistant Professor in Oncology, UUCM AMC
- Clinical Instructor in UUCM AMC
- Fellowship in UUCM AMC
- Residency in UUCM AMC
- Internship in UUCM AMC
Hospital
Asan Medical Centre, Seoul, South Korea
Specialization
- Breast cancer
- Bone & soft tissue sarcoma
- Cervical cancer
- Vaginal cancer
- Ovarian cancer
Procedures Performed
- Breast cancer treatment
- Bone & soft tissue sarcoma treatment
- Cervical cancer treatment
- Vaginal cancer treatment
- Ovarian cancer treatment
Research & Publications
| Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. |
| Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive |
| A Randomized Feasibility Study of (18)F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer. |
| Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer. |
| Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. |
| Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline. |
| A randomized feasibility study of 18F-fluoroestradiol positron emission tomography to predict pathological response to neoadjuvant systemic therapy in estrogen receptor-rich postmenopausal breast cancer. |
| Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer. |
| Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. |
| Monogenic and polygenic determinants of sarcoma risk: an international genetic study. |
| Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. |
| Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change aft |
| Postoperative Radiotherapy After Limb-sparing Surgery for Soft-tissue Sarcomas of the Distal Extremities. |
| A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer. |
| Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. |
| Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab |
| Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers |
| High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers |
| Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. |
| Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. |
